Lupin-led arm to acquire Sunovion Pharma's Brovana and Xopenex HFA brands

20 Oct 2022 , 09:19 AM

Lupin Limited informed that its wholly owned subsidiary Lupin Inc., USA, is acquiring all assets required to manufacture and commercialize Brovana (Arformoterol Tartrate) Inhalation Solution and Xopenex HFA (Levalbuterol Tartrate) Inhalation Aerosol in the United States.

The acquisition of said brands will expand Lupin’s portfolio of Inhalation products. The company stated that the acquisition is expected to be completed 2-3 weeks post-signing.

Lupin Inc will acquire the said brands for USD 75 million (approx. Rs622.40 crore).

“We remain focused on growing our respiratory business in the United States,” said Lupin CEO Vinita Gupta. With the launch of Albuterol MDI and Brovana-approved generics, we have built a solid position in the respiratory category. The inclusion of these two brands strengthens our market position.”

Brovana can be used for the long-term maintenance therapy of bronchoconstriction in individuals suffering from chronic obstructive pulmonary diseases, such as chronic bronchitis and emphysema.

Xopenex HFA is a beta2-adrenergic agonist (SABA) with a short half-life intended for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age and older with reversible obstructive airway disease.

As per the MAT August 2022 data, IQVIA sales for the two brands combined were approximately $60 million.

At around 9.23 AM, Lupin was trading at Rs683.55 down by 0.66% from its previous closing of Rs688.10 on the BSE. The scrip opened at Rs673.85 and touched intraday high and low of Rs684 and Rs670.65 respectively.

For feedback and suggestions, write to us at [e-mail]